XTLB — X T L Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $9.43m
- $9.26m
- $0.45m
Annual income statement for X T L Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.451 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.003 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.948 | 1.03 | 0.88 | 0.765 | 2.62 |
| Operating Profit | -0.948 | -1.03 | -0.88 | -0.765 | -2.17 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.95 | 0.435 | -1.35 | -1.78 | -1.16 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.95 | 0.435 | -1.35 | -1.78 | -1.03 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.95 | 0.435 | -1.35 | -1.78 | -1.03 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.95 | 0.435 | -1.35 | -1.78 | -1.03 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.006 | 0.001 | -0.002 | -0.003 | -0.002 |